Vasomotor and  -block negating actions of a hydroxamic acid.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology; D002934:Cinnamates / Q000494:pharmacology; D004285:Dogs; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*; D006898:Hydroxylamines / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D010643:Phenoxybenzamine / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000187:drug effects; D013565:Sympatholytics / Q000494:pharmacology*; D013997:Time Factors; D014666:Vasomotor System / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002934:Cinnamates; D006634:Histamine H1 Antagonists; D006877:Hydroxamic Acids; D006898:Hydroxylamines; D013565:Sympatholytics; D010643:Phenoxybenzamine; D001285:Atropine; D010830:Physostigmine; D007545:Isoproterenol; D002746:Chlorpromazine; D004837:Epinephrine